RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 133 filers reported holding RECURSION PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.76 and the average weighting 2.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $234,281 | +0.7% | 30,625 | -1.6% | 0.00% | 0.0% |
| Q2 2023 | $232,564 | +84.0% | 31,133 | +64.3% | 0.00% | 0.0% |
| Q1 2023 | $126,423 | -13.5% | 18,954 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $146,135 | -8.1% | 18,954 | +26.7% | 0.00% | 0.0% |
| Q3 2022 | $159,000 | +29.3% | 14,957 | -1.2% | 0.00% | 0.0% |
| Q2 2022 | $123,000 | -55.3% | 15,144 | -5.7% | 0.00% | 0.0% |
| Q4 2021 | $275,000 | +52.8% | 16,065 | +105.3% | 0.00% | 0.0% |
| Q3 2021 | $180,000 | – | 7,826 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Obvious Management Services, L.L.C. | 5,977,631 | $42,800,000 | 100.00% |
| Two Sigma Ventures, LP | 1,806,800 | $12,937,000 | 74.73% |
| DCVC Opportunity Fund II GP, LLC | 3,951,141 | $28,290,000 | 31.54% |
| MV Management XI, L.L.C. | 1,971,908 | $14,119,000 | 9.80% |
| Data Collective IV GP, LLC | 5,941,120 | $42,538,000 | 9.03% |
| ArchPoint Investors | 1,267,430 | $9,075,000 | 3.13% |
| MIC Capital Management UK LLP | 1,388,889 | $9,944,000 | 1.94% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $10,806,000 | 1.09% |
| Samsara BioCapital, LLC | 539,236 | $3,861,000 | 0.97% |
| Pinz Capital Management, LP | 142,168 | $1,018,000 | 0.64% |